Drug Profile
Research programme: protein therapeutics - Lee's Pharmaceutical
Alternative Names: ZK002Latest Information Update: 23 Feb 2023
Price :
$50
*
At a glance
- Originator Lee's Pharmaceutical
- Class Proteins
- Mechanism of Action Angiogenesis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Cancer; Eye disorders
Most Recent Events
- 23 Feb 2023 Discontinued - Preclinical for Eye disorders in China (Ophthalmic) (Lee's Pharmaceutical pipeline, February 2023)
- 28 Nov 2019 No recent reports of development identified for preclinical development in Eye-disorders in China (Ophthalmic)
- 21 Mar 2012 Preclinical trials in Cancer in Hong Kong (unspecified route)